The adoption of decentralized and agile clinical trials has increased exponentially over the past few years. As adoption accelerates, so do the possibilities that a decentralized clinical trial (DCT) enables. Oncology trials have especially benefited with DCT practices.
In this webinar, Dr. Shaalan Beg, MD, MS, Vice President, Oncology, at Science 37 will host a conversation with a group of industry leaders, discussing what current clinical research looks like with oncology trials. The panel will share the value that agile approaches deliver to patients, sponsors, sites and CROs — giving examples of how decentralized elements are incorporated in oncology trials today, and how the landscape will change in the years to come.
Register to learn what oncology trials look like now with the adoption of decentralized practices.
James Chase (Moderator), Senior Director, Thought Leadership, Science 37
James is responsible foretelling Science 37’s story and for sharing the unique knowledge and expertise of its thought leaders. A seasoned journalist, editor and content strategist, James has spent more than 20 years in business media, having moved to the U.S. from the U.K in 1998 as part of the launch team of PR Week. After helping to roll out digital marketing title Revolution two years later, James wound up at Medical Marketing & Media, where he spent nine years as editor in chief, overseeing the launch of many successful initiatives, including the MM&M Awards. Prior to joining Science 37, James was digital director at Ad Age, where he oversaw the title’s website (which won the coveted Jesse Neal Award for Website of the Year in both 2020 and 2021). Outside of content, James is obsessed with following a dreadful third-tier soccer team in the U.K., spicy food, music, going to shows, traveling and pretending to be a runner.Message Presenter
Dr. Shaalan Beg, MD, MS, Vice President, Oncology, Science 37
Dr. Shaalan Beg, MD, MSCS, Science 37 Global Management Team, comes to Science 37 from the University of Texas, Southwestern Medical Center in Dallas, Texas where he served as Medical Director for the Clinical Research Office at the Simmons Comprehensive Cancer Center and held the position of Director Gastrointestinal (GI) Medical Oncology and Associate Professor of Hematology and Medical Oncology. Nationally, Dr. Beg is a member of the American Society of Clinical Oncology (ASCO) and the ECOG-ACRIN Clinical Research Group and has held various committee positions in these organizations. He is a graduate of ASCO’s Leadership Development Program and has been a member of the Pancreatic Cancer Task Force of the National Cancer Institute (NCI) GI Cancer Steering Committee.Message Presenter
Who Should Attend?
Therapeutic Leads – Oncology, R&D, Clinical Operations
What You Will Learn
Attendees will gain insights into:
- New ways to operationalize hybrid oncology trials
- How virtual sites help reduce patient burden
- Where the industry is headed with decentralized clinical trials and oncology
Science 37, Inc.’s (Nasdaq: SNCE) mission is to enable universal access to clinical research, making it easier for patients and providers to participate from anywhere. Since 2014, we’ve pioneered decentralized and agile clinical trial approaches and having conducted more than 125 agile clinical trials, we’re helping forge the future of research. The Science 37 Operating System (OS) supports today’s more agile clinical research design, enabling up to 15x faster enrollment, 28% better retention, and 3x more diverse patient population.